MedMatrix Rx
340B Morning Briefing for Executives
The 340B program faces significant changes as HRSA prepares to launch a 340B Rebate Model Pilot, requiring covered entities to pay the Wholesale Acquisition Cost (WAC) and seek rebates starting January 1, 2027. This development has prompted drugmakers, including AbbVie and Bristol Myers Squibb, to seek intervention in a lawsuit against HRSA’s rebate model. Concurrently, CMS has proposed cuts to 340B drug payments, which could reduce Original Medicare drug payments by $4.55 billion in 2027. Concerns regarding the program’s expansion beyond its original intent have also been raised by HHS, citing issues such as spread pricing and consolidation. In response to these changes, bipartisan lawmakers have introduced a bill to delay the rebate pilot for two years, pending broader reforms to the 340B program.
EXECUTIVE SUMMARY
01
HRSA to launch 340B Rebate Model Pilot.
HRSA plans a 340B Rebate Model Pilot requiring covered entities to pay WAC and seek rebates, starting January 1, 2027.
HRSA plans a 340B Rebate Model Pilot requiring covered entities to pay WAC and seek rebates, starting January 1, 2027.
Source: Norton Rose Fulbright
02
Drugmakers seek to join 340B rebate lawsuit.
AbbVie, Bristol Myers Squibb, and PhRMA filed motions to intervene in the lawsuit against HRSA’s 340B rebate model.
AbbVie, Bristol Myers Squibb, and PhRMA filed motions to intervene in the lawsuit against HRSA’s 340B rebate model.
Source: Becker’s Hospital Review
03
CMS proposes 340B payment cuts.
CMS’s proposed rule would cut 340B drug payments, potentially reducing Original Medicare drug payments by $4.55 billion in 2027.
CMS’s proposed rule would cut 340B drug payments, potentially reducing Original Medicare drug payments by $4.55 billion in 2027.
Source: Becker’s Hospital Review
04
HHS flags 340B program concerns.
HHS reports the 340B program has expanded beyond its original intent, raising concerns about spread pricing and consolidation.
HHS reports the 340B program has expanded beyond its original intent, raising concerns about spread pricing and consolidation.
Source: TechTarget
05
New bill to delay 340B rebate pilot.
Bipartisan lawmakers introduced a bill to delay HRSA’s 340B rebate pilot for two years, pending broader 340B reforms.
Bipartisan lawmakers introduced a bill to delay HRSA’s 340B rebate pilot for two years, pending broader 340B reforms.
Source: Becker’s Hospital Review
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The proposed changes to the 340B program, particularly the introduction of the rebate model and potential payment cuts, present significant challenges for covered entities. These developments could strain financial resources, as entities may face increased costs associated with paying WAC and the rebate process. The proposed cuts to Medicare drug payments could further exacerbate financial pressures, potentially limiting access to affordable medications for vulnerable populations. As covered entities adapt to these changes, they may need to reassess their operational strategies and financial planning to mitigate the impact of reduced reimbursements and increased administrative burdens.
Emerging risks.
- The 340B rebate model pilot could impose over $1 billion in administrative costs annually on hospitals.
- Hospitals may face cash flow issues due to upfront drug purchasing costs under the new rebate model.
- CMS’s proposed 340B payment cuts could result in significant financial losses for health systems.
- The expansion of the 340B program may incentivize hospital consolidation, raising healthcare costs.
- Legal challenges to the rebate model could delay its implementation, creating uncertainty for stakeholders.
Emerging opportunities.
- Hospitals could use the delay in the 340B rebate pilot to advocate for more favorable terms.
- The proposed payment cuts may encourage hospitals to optimize their drug purchasing strategies.
- Stakeholders can engage with lawmakers to influence potential reforms to the 340B program.
- Hospitals may explore alternative funding sources to mitigate the impact of reduced 340B savings.
- The ongoing litigation provides a platform for hospitals to discuss the program’s importance to patient care.
Key actions for providers.
- Hospitals should prepare for potential changes in 340B reimbursement models and their financial implications.
- Engage with policymakers to communicate the impact of 340B changes on patient care and hospital operations.
- Monitor legal proceedings and legislative developments related to the 340B rebate pilot.
- Evaluate financial strategies to manage cash flow challenges under the new rebate model.
- Consider partnerships with other healthcare entities to strengthen advocacy efforts for 340B reforms.
TOP STORIES
CMS proposes 340B payment cuts.
Becker’s Hospital Review · October 12, 2026
- CMS’s proposed rule would cut 340B drug payments by $4.55 billion in 2027.
- Health systems estimate losses ranging from $7 million to $109 million annually.
- The rule aims to pay hospitals ASP minus 33.4% for 340B drugs.
- CMS plans to offset cuts by raising payments for nondrug outpatient services.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
HHS flags 340B program concerns.
TechTarget · October 12, 2026
- HHS reports the 340B program prioritizes profit over patient care.
- The program’s growth may drive hospital consolidation and increased costs.
- ASPE supports CMS’s proposed reimbursement cuts to address these issues.
- Hospitals argue the program is essential for safety-net providers.
New bill to delay 340B rebate pilot.
Becker’s Hospital Review · October 13, 2026
- Bipartisan lawmakers introduced the 340B Rebate Model Delay Act.
- The bill would pause the rebate pilot from 2027 to 2028.
- It bars federal funds for implementing similar rebate programs.
- The pause allows Congress to consider broader 340B reforms.
ASPE critiques 340B program’s growth.
TechTarget · October 12, 2026
- ASPE suggests the 340B program’s growth incentivizes consolidation.
- The report details increased program costs and participation.
- ASPE calls for aligning Medicare reimbursements with acquisition costs.
- The report raises concerns about anticompetitive behavior in healthcare.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D. Me. | AMERICAN HOSPITAL ASSOCIATION v. KENNEDY — Brief of Amici Curiae by 340B health, america’s essential hospitals, association of american medical colleges, children’s hospital association. Case filed October 9, 2026. [source] | October 20, 2026 |
| M.D. Fla. | Florida Health Sciences Center, Inc. v. Eli Lilly and Company — Response to Motion re motion to Dismiss Plaintiff’s Complaint and As-Applied Challenge to the Constitutionality of Section 501.201 to 501.213, Fla. Stat. Case filed July 2, 2026. [source] | October 14, 2026 |
| S.D.N.Y. | Mount Sinai Hospital v. CVS Health Corporation — Protective ORDER.regarding procedures to be followed that shall govern the handling of confidential material. (.). Case filed May 18, 2026. [source] | October 13, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Surreply to Reply to 5 motion for Preliminary Injunction Def’s Surreply in Opposition to Plt’s Motion for Preliminary Injunction. Case filed July 27, 2026. [source] | October 6, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
SOCIAL MEDIA & STAKEHOLDER SENTIMENT
Identified recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, including reactions, statements, op-eds, and advocacy positions from various groups and platforms.
ADAP Advocacy Calls for CMS Oversight of 340B Drug Pricing Program
Burstable.News · July 27, 2026
- Main theme: Advocacy for CMS oversight of 340B program due to transparency and enforcement concerns.
- Stakeholder sentiment: ADAP Advocacy urges transferring oversight from HRSA to CMS, citing lack of transparency and enforcement.
- Potential implications: Potential shift in program oversight to address transparency and enforcement issues.
- Credibility: Burstable.News is a curated news platform providing aggregated articles from various sources.
340B Stakeholder Comments: Pharma-Funded Template Duplication Concerns
340B Report · August 2026
- Main theme: Concerns over duplicate stakeholder comments linked to pharma-funded templates.
- Stakeholder sentiment: 340B Report notes duplication in comments, suggesting influence from pharma-funded templates.
- Potential implications: Potential questioning of the authenticity and independence of stakeholder feedback.
- Credibility: 340B Report is a specialized publication focusing on 340B program developments.
340B Drug Pricing Program Expert Discussion with Shawn Gremminger and Tom Kraus
Drug Topics · August 2026
- Main theme: Expert debate on the 340B program’s role and policy implications.
- Stakeholder sentiment: Shawn Gremminger and Tom Kraus discuss the program’s role and policy implications.
- Potential implications: Insights into the regulatory changes affecting health systems and patients.
- Credibility: Drug Topics is a reputable publication covering pharmaceutical industry news.
The 2027 OPPS 340B Cut is a Safety-Net Strategy Crisis, Not a Drug Pricing Footnote
LinkedIn · August 27, 2026
- Main theme: Concerns over proposed 340B reimbursement cuts impacting safety-net providers.
- Stakeholder sentiment: Deepa Yerram expresses concern over proposed cuts threatening care models for uninsured patients.
- Potential implications: Potential disruption to care models for uninsured and underinsured patients.
- Credibility: LinkedIn post by Deepa Yerram, MD, MHA, CPHQ, FAAFP, a healthcare professional.
WHAT TO WATCH NEXT
- HRSA’s 340B Rebate Model Pilot is set to begin on January 1, 2027. [source]
- CMS’s proposed 340B payment cuts are expected to take effect in 2027. [source]
- The American Hospital Association’s lawsuit against HRSA’s rebate model is ongoing in the District of Maine. [source]
- Drugmakers’ motions to intervene in the 340B rebate lawsuit are pending court approval. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.